Probiotics may tame nausea from popular Weight-Loss shots
NCT ID NCT07213323
First seen Jun 25, 2026 · Last updated Aug 20, 2026 · Updated 3 times
Summary
This study tests whether taking probiotics can reduce digestive side effects like nausea and diarrhea in people starting weight-loss drugs such as semaglutide or tirzepatide. Fifty adults with obesity will take either a probiotic capsule or a placebo daily for 26 weeks. The goal is to see if probiotics help maintain a better quality of life during the first few months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Probiotics (dietary supplement)
- What this could lead to
- If it works, this could offer a simple way to reduce nausea and stomach issues from popular weight-loss drugs, helping people stay on treatment longer.
- What could go wrong
- This is a small, early-stage trial with only 50 people. Probiotics may not help everyone, and the study hasn't started yet, so results are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient who is going to start a GLP-1 RA (semaglutide or tirzepatide) for weight management * Men or Women * BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 associated with one or more co-morbidities (arterial hypertension, sleep apnea, dyslipidemia, arthritis) * Between 18 and 75 years old * In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, ability to understand and fill the self-rating scales, drug compliance, availability to attend to the scheduled visits, etc…). * Patient who agrees to be included in the study and who signs the informed consent form * Female participants of childbearing potential must agree to use effective contraception * Patient affiliated to a healthcare insurance plan Exclusion Criteria: Criteria relating to the study population: * Patients under 18 years old * Patient with contraindication to semaglutide or tirzepatide according to the Summary of Product Characteristics (SPC). * Patients scheduled for bariatric surgery during the study period * Patients who have had bariatric surgery in the last 12 months * Patient with a current diagnosis of diabetes. * Patients with a current diagnosis of liver cirrhosis, short bowel syndrome or inflammatory bowel disease (IBD). * Patients with severely weakened immune system. * Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease. Product criteria: Patient with known allergy to the product of the study Prohibited treatments : Current associated treatments or used in the last 30 days: GLP-1 RA, Anti-obesity drugs (AOD), Corticosteroids, Atypical neuroleptics, Antibiotics, Probiotics, Prebiotics Regulatory criteria : * Persons deprived of their liberty by a judicial or administrative decision * Persons under psychiatric care * Persons admitted to a health or social institution for purposes other than research * Adults subject to a legal protection measure (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme * Subjects participating in other interventional research with an exclusion period still in progress at pre-inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Digestive disorders are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Lyon Sud
RECRUITINGPierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Emergency room visit could be a turning point for metabolic health
- Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?
- Pedal-Assist E-Bikes may boost fitness and cut fat in sedentary students
- New program helps seniors in camden fight obesity and pain without drugs
- Exercise boosts Weight-Loss surgery results, study finds
- Obesity drug VCT220 put to the test: will common meds interfere?